Curon Medical
This article was originally published in The Gray Sheet
Executive Summary
Initial public offering proceeds increase to $60.2 mil. following exercise of 475,000-share overallotment option, announced Oct. 14. The Sunnyvale, California maker of the Stretta radiofrequency system for gastroesophageal reflux disease initially went public Sept. 22 via an offering of 5 mil. shares at $11 each (1"The Gray Sheet" Oct. 2, 2000, p. 16). A portion of the proceeds will be used to build up the company's sales force for marketing the Stretta system, cleared by FDA via 510(k) in April. Underwriters included lead manager UBS Warburg LLC and co-managers CIBC World Markets and SG Cowen
You may also be interested in...
Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO
Curon Medical will use $2 mil. of its $55 mil. initial public offering for sales and marketing initiatives related to its recently launched Stretta radiofrequency system for gastroesophageal reflux disease (GERD), according to a Sept. 22 IPO prospectus filed with the Securities and Exchange Commission.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.